touchCONGRESS

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

Access to this content is not permitted for healthcare professionals based in the UK, US or Japan

Back to Home

This activity is for healthcare professionals outside of the UK, USA and Japan.

This activity is provided by an independent medical education grant from Novartis. This activity is provided by touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Download Slides
    Download Fact Sheet
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Gianantonio Rosti

    IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy

    Prof. Gianantonio Rosti is a senior scientist at the IRCCS Istituto Romagnolo per lo Studio dei Tumori  “Dino Amadori” in Meldola, Italy, a position he has held since 2021. read more

    Prof. Rosti graduated in Medicine and Surgery at the University of Bologna, after which he became a fellow at the Johns Hopkins University Hospital in Baltimore, USA. He then spent 5 years as a medical assistant at the Institute of Hematology ‘L. and A. Seràgnoli’, Bologna University, S. Orsola Hospital in Bologna, Italy, where he retains the position of first level medical assistant. 

    As a clinical trials expert (Good Clinical Practice; International Committee on Harmonization [GCP IHC]), Prof. Rosti’s specific scientific pursuits include serving as the scientific secretary to the former Italian Cooperative Group for Chronic Myelogenous Leukemia (now the Italian Group For Adult Hematologic Malignancies [GIMEMA] Chronic Myeloid Leukemia Working Party [CML WP]). Prof. Rosti is a member of the European Investigators on CML (EICML) and the European LeukemiaNet (ELN) writing panel for ELN recommendations (2013, 2020 and 2023). He also serves on the steering committee for the EUropean Treatment and Outcome Study (EUTOS) population-based registry. In addition, he has authored or co-authored more than 250 scientific papers and meetings abstracts.

    Prof. Gianantonio Rosti discloses: Advisory board/panel fees from Incyte, Novartis and Sun Pharma. Grants/research support and speaker’s bureau fees from Incyte, Novartis, Pfizer and Sun Pharma.
    Dr Carla Boquimpani

    Fundação Saúde do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

    Dr Carla Boquimpani, a haematologist, is a technical director of the Fundação Saúde do Estado do Rio de Janeiro, and a manager of public state hospitals for the State Institute of Hematology Arthur de Siqueira Cavalcanti (HEMORIO), both in Rio de Janeiro, Brazil. She also serves as a leader in the management of chronic leukaemias at Oncoclínicas do Brasil Servicos Medicos SA in Brazil. read more

    Dr Boquimpani graduated in medicine from the Federal University of Rio de Janeiro (UFRJ) in Brazil. She completed her residency in haematology at HEMORIO and a masters in haematology at UFRJ. She was a technical director at HEMORIO, where she specialized in the treatment of patients with chronic myeloid leukaemia (CML). She has served as a principal investigator on several international clinical trials in CML, including those evaluating interruptions in treatment with third-generation tyrosine kinase inhibitors. 

    Dr Boquimpani is a member of the Brazilian CML Group and the Latin American Leukemia Net (LALNET). She has published several articles and presented at numerous conferences on the treatment of CML.

    Dr Carla Boquimpani discloses: Advisory board/panel fees from Janssen and Novartis. Speaker’s bureau fees from Janssen, Novartis, Pfizer and Pint Pharma.
    Prof. Dr. med. Susanne Saussele

    University of Mannheim, Mannheim, Germany

    Prof. Susanne Saussele is head of the CML Excellence Center at Mannheim University Hospital in Mannheim, Germany, including the molecular laboratory and the Study Centre for Hematology at the Mannheim Cancer Center. She is also chief resident of the polyclinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, Mannheim. In 2017, she was appointed professor at the University of Heidelberg. read more

    Prof. Saussele is a project leader at EUropean Treatment and Outcome Study of CML (EUTOS) and is a member of the European LeukemiaNet Chronic Myeloid Leukemia (ELN-CML) working party. In addition, she is a member of the Scientific Program Committee of German Society for Hematology and Medical Oncology (DGHO). From 2014 to 2019, she served as a member of the Scientific Program Committee of the European Hematology Association (EHA).

    Prof. Dr. med. Susanne Saussele discloses: Advisory board/panel fees from Incyte, Novartis, Pfizer and Roche. Grants/research support from BMS, Incyte and Novartis.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Start activity

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    Which emerging TKI for CML has the greatest potential to impact daily practice?

    Submit your answer to see the results

    ELVN-001
       
    Olverembatinib
       
    Ruxolitinib
       
    None of these will have a notable impact
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    Which of these do you initiate most often to treat CML in the third line?

    Submit your answer to see the results

    Asciminib
       
    Ponatinib
       
    A different TKI (first- or second-generation)
       
    A non-TKI therapy
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    Which TKI do you initiate most often in the first line for your patients with CML?

    Submit your answer to see the results

    Imatinib
       
    Bosutinib
       
    Dasatinib
       
    Nilotinib
       
     
    Take CE/CME Test

    touchCONGRESS
    Our faculty interpret key data from the congress, complimented by an expert panel discussing what has been presented. Close

    Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • Downloads including slides are available for this activity in the Toolkit

    • A fact sheet is available for this activity in the Toolkit.

    Learning Objectives

    After watching this activity, participants should be better able to:

    • Evaluate the latest data for approved and emerging tyrosine kinase inhibitors for chronic myeloid leukaemia in the first-line setting
    • Discuss the data for approved and emerging tyrosine kinase inhibitors for chronic myeloid leukaemia in the second- and later-line settings
    • Summarize the potential impact of emerging findings from clinical trials and real-world studies on current and future clinical practice in chronic myeloid leukaemia
    Overview

    In this activity, an expert in chronic myeloid leukaemia (CML) reviews important data on approved and emerging agents for CML from key 2024 congresses, and discusses with two additional leading experts how this evidence may apply to clinical practice.

    This activity was filmed following the ESH-iCMLf annual conference (Prague, Czech Republic, 27–29 September 2024) and is based on data from this meeting plus ASCO 2024 and EHA 2024.

    This activity is provided by touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of haematologists, including haemato-oncologists, and oncologists involved in the management of chronic myeloid leukemia (CML).

    Faculty

    Prof. Gianantonio Rosti discloses: Advisory board/panel fees from Incyte, Novartis and Sun Pharma. Grants/research support and speaker’s bureau fees from Incyte, Novartis, Pfizer and Sun Pharma.

    Dr Carla Boquimpani discloses: Advisory board/panel fees from Janssen and Novartis. Speaker’s bureau fees from Janssen, Novartis, Pfizer and Pint Pharma.

    Prof. Dr. med. Susanne Saussele discloses: Advisory board/panel fees from Incyte, Novartis, Pfizer and Roche. Grants/research support from BMS, Incyte and Novartis.

    Touch Medical Contributors

    Sola Neunie and Johanna Barry have no financial interests/relationships or affiliations in relation to this activity.

    Date of original release: 28 October 2024. Date credits expire: 28 April 2026.

    Time to Complete: 50 minutes

    This activity is CE/CME accredited

    To obtain the credit(s) from this activity, please complete this post-activity test.

    Claim Credit

    Course Modules

    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Spanish.
    • Downloads including slides are available for this activity in the Toolkit

    • A fact sheet is available for this activity in the Toolkit.

    You may also be interested in...

    CONFERENCE HUB

    Binod Dhakal, ASCO 2023: The CARTITUDE-4 trial, ciltacabtagene autoleucel for patients with lenalidomide-refractory multiple myeloma

    GO TO HUB

    touchCONGRESS

    Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

    LAUNCH ACTIVITY

    touchCONGRESS

    Advancing the treatment of MDS and AML: An update from ASH 2021

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Shaji Kumar, ASH 2020 – Highlights from ASH 2020

    GO TO HUB

    JOURNALS

    Nilotinib Therapy in Patients with Chronic Myeloid Leukemia Who Have Failed Imatinib

    GO TO ARTICLE

    JOURNALS

    Radioimmunotherapy – A New Approach in the Management of Non-Hodgkin’s Lymphoma

    GO TO ARTICLE

    Topics covered in this activity

    Leukaemia / Haematological Malignancies
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This activity is funded by:

    An independent medical education grant from Novartis.
    This activity is provided by touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 28 October 2024. Date credits expire: 28 April 2026.

    Claim Credit
    touchCONGRESS
    Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

    You may also be interested in...

    touchCONGRESS

    Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

    LAUNCH ACTIVITY

    CONFERENCE HUB

    John Mascarenhas, ASH 2022: Treatment challenges in myelofibrosis and severe thrombocytopenia and the rationale for the use of pacritinib

    GO TO HUB

    touchIN CONVERSATION

    Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Petra Langerbeins PhD, EHA 2019 – Results of the Phase III Double-blind Randomised CLL12 Trial

    GO TO HUB

    JOURNALS

    Obstacles to Clinical Research

    GO TO ARTICLE

    JOURNALS

    Serum Free Light Chain Assays—Their Role in Multiple Myeloma

    GO TO ARTICLE
    This activity is funded by:

    An independent medical education grant from Novartis.
    This activity is provided by touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 28 October 2024. Date credits expire: 28 April 2026.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup